A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2009-01-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-009-0927-7PMID 19169683
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Design and endpoints of clinical trials in hepatocellular carcinoma.

  2008cited by this paper
• HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer

  2008cited by this paper
• Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

  2008cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer

  2008cited by this paper
• Multi-disciplinary treatment for cholangiocellular carcinoma.

  2007cited by this paper
• Treatment options for hepatobiliary and pancreatic cancer.

  2007cited by this paper
• Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).

  2007cited by this paper
• Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

  2007cited by this paper
• Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

  2007influential reference
• New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system

  2007cited by this paper
• Origin and prognostic value of circulating KRAS mutations in lung cancer patients.

  2007cited by this paper
• Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

  2007cited by this paper
• Phase II study of erlotinib in patients with advanced biliary cancer.

  2006cited by this paper
• A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma

  2006cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• Heparin-binding Epidermal Growth Factor-like Growth Factor Links Hepatocyte Priming with Cell Cycle Progression during Liver Regeneration*

  2005cited by this paper
• Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis

  2005cited by this paper
• Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

  2005influential reference
• Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

  2005cited by this paper
• Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells.

  2005cited by this paper
• Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy

  2005cited by this paper
• Epidermal growth factor receptor (EGFR) gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation

  2004cited by this paper
• Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells.

  2004cited by this paper
• ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model.

  2003cited by this paper
• Induction of the Estrogen Receptor by Ablation of DNMT1 in ER-Negative Breast Cancer Cells

  2003cited by this paper
• Frequent k- ras -2 mutations and p16INK4Amethylation in hepatocellular carcinomas in workers exposed to vinyl chloride

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression.

  2000cited by this paper
• Modulation of Epidermal Growth Factor Receptor Gene Transcription by a Polymorphic Dinucleotide Repeat in Intron 1*

  1999cited by this paper
• Optimal two-stage designs for phase II clinical trials.

  1989cited by this paper

• Mismatch Repair Protein and Microsatellite Instability Analysis in Pancreatic Ductal Adenocarcinoma.

  2026cites this paper
• Safety and Efficacy of Anti–Human Epidermal Growth Factor 2 Agents in the Treatment of Biliary Tract Cancers: A Systematic Review

  2025cites this paper
• Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

  2025cites this paper
• EGFR activation in cholangiocytes promotes extrahepatic bile duct regeneration after injury

  2025cites this paper
• Systemic therapy for pretreated advanced biliary tract cancer: past developments and recent advances.

  2025cites this paper
• HER2-Targeted Therapies: Unraveling Their Role in Biliary Tract Cancers.

  2025cites this paper
• A chalcone/quinolone hybrid drug (COQM) triggers oxidative stress, DNA damage, and apoptosis to induce selective antiproliferative effects in breast cancer cells

  2025cites this paper
• EGFR activation in cholangiocytes promotes extrahepatic bile duct regeneration after injury

  2025cites this paper
• Epigenetic Regulation and Targeted Therapy in Gall Bladder Cancer

  2025cites this paper
• Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives.

  2024cites this paper
• HER2 Overexpression in Periampullary Tumors According to Anatomical and Histological Classification—A Systematic Review

  2024cites this paper
• A pyroptosis-related lncRNA-based prognostic index for hepatocellular carcinoma by relative expression orderings

  2024cites this paper
• Management of Intrahepatic Cholangiocarcinoma: A Narrative Review

  2024cites this paper
• Comprehensive single-cell analysis deciphered microenvironmental dynamics and immune regulator olfactomedin 4 in pathogenesis of gallbladder cancer

  2024cites this paper
• New perspectives in biliary tract cancers

  2024cites this paper
• Cucurbitacin I exerts its anticancer effects by inducing cell cycle arrest via the KAT2a-ube2C/E2F1 pathway and inhibiting HepG2-induced macrophage M2 polarization.

  2024cites this paper
• Perioperative and palliative systemic treatments for biliary tract cancer

  2024influential citation
• Mechanisms and therapeutic targets of ErbB family receptors in hepatocellular carcinoma: a narrative review

  2024cites this paper
• Targeting AFP-RARβ complex formation: a potential strategy for treating AFP-positive hepatocellular carcinoma

  2024cites this paper
• EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance

  2024cites this paper
• Mutation-based therapies for intrahepatic cholangiocarcinoma: new options on the horizon

  2024cites this paper
• Synthesis and Anticancer Evaluation of 4-Anilinoquinolinylchalcone Derivatives

  2023cites this paper
• Machine learning integrations develop an antigen-presenting-cells and T-Cells-Infiltration derived LncRNA signature for improving clinical outcomes in hepatocellular carcinoma

  2023cites this paper
• Novel precision therapies for cholangiocarcinoma: an overview of clinical trials

  2023cites this paper
• Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma

  2023cites this paper
• Research trends in cholangiocarcinoma treatments during the last 3 decades

  2023cites this paper
• The Role of HER2 Status in the Biliary Tract Cancers

  2023cites this paper
• Molecular pathology for cholangiocarcinoma: a review of actionable genetic targets and their relevance to adjuvant & neoadjuvant therapy, staging, follow-up, and determination of minimal residual disease

  2023cites this paper
• NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.

  2023cites this paper
• Muscarinic Receptors Associated with Cancer

  2022cites this paper
• Targeted Therapies for Perihilar Cholangiocarcinoma

  2022cites this paper
• The state of therapy modalities in clinic for biliary tract cancer.

  2022cites this paper
• Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

  2022cites this paper
• Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications

  2022cites this paper
• Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.

  2022cites this paper
• Treatment of biliary tract carcinoma over the last 30 years.

  2022cites this paper
• Addition of trastuzumab emtansine (T-DM1) in a human epidermal growth factor receptor 2–overexpressed metastatic carcinoma of the gallbladder patient to enhance survival: A case study

  2022cites this paper
• Prognostic and Predictive Molecular Markers in Cholangiocarcinoma

  2022cites this paper
• HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer

  2022cites this paper
• Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient

  2022influential citation
• Treating Biliary Tract Cancers: New Targets and Therapies

  2022cites this paper
• Evolving Paradigms in the Systemic Treatment of Advanced Gallbladder Cancer: Updates in Year 2022

  2022cites this paper
• Current and emerging therapies for advanced biliary tract cancers.

  2021cites this paper
• Current State of Multidisciplinary Treatment in Cholangiocarcinoma

  2021cites this paper
• Cholangiocarcinoma: shedding light on the most promising drugs in clinical development

  2021cites this paper
• Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview

  2021cites this paper
• Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer

  2021cites this paper
• Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp)

  2021cites this paper
• Targeting HER2 in Biliary Tract Carcinomas: Challenges and Opportunities

  2021cites this paper
• Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials

  2021cites this paper
• Cell of origin in biliary tract cancers and clinical implications

  2021cites this paper
• Insights into Growth Factors in Liver Carcinogenesis and Regeneration: An Ongoing Debate on Minimizing Cancer Recurrence after Liver Resection

  2021cites this paper
• Regulation on tumor metastasis by Raf kinase inhibitory protein: New insight with reactive oxygen species signaling

  2021cites this paper
• Novel Targeted Therapies in Clinical Use and on the Horizon for Cholangiocarcinoma

  2021cites this paper
• Optimal tissue sampling during ERCP and emerging molecular techniques for the differentiation of benign and malignant biliary strictures

  2021cites this paper
• In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma

  2021cites this paper
• Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond

  2021cites this paper
• Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers

  2021cites this paper
• Primary Sclerosing Cholangitis–Associated Cholangiocarcinoma Demonstrates High Intertumor and Intratumor Heterogeneity

  2021cites this paper
• Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development

  2021cites this paper
• Fortschritte bei der Personalisierung der Systemtherapie hepatobiliärer Tumoren

  2021influential citation
• The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines

  2021cites this paper
• EGFR and HER2neu Expression in Gall Bladder Carcinoma and Its Association with Clinicopathological Parameters - An Institutional Experience from North India

  2021cites this paper
• Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.

  2021cites this paper
• Molecular-driven treatment for biliary tract cancer: the promising turning point

  2021cites this paper
• Targets for therapy in biliary tract cancers: the new horizon of personalized medicine.

  2020cites this paper
• New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma

  2020cites this paper
• Molecular targeted therapies: ready for "prime time" in biliary tract cancer.

  2020cites this paper
• The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapy.

  2020cites this paper
• Near‐infrared photoimmunotherapy (NIR‐PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes

  2020cites this paper
• Personalisierte Therapie des cholangiozellulären Karzinoms

  2020cites this paper
• ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway

  2020cites this paper
• Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.

  2020cites this paper
• Current and New Biomarkers for Early Detection, Prognostic Stratification, and Management of Gallbladder Cancer Patients

  2020cites this paper
• Expression of Female Sex Hormone Receptors, Connective Tissue Growth Factor and HER2 in Gallbladder Cancer

  2020cites this paper
• Systemic treatment of advanced or recurrent biliary tract cancer.

  2020cites this paper
• Overview of current targeted therapy in gallbladder cancer

  2020cites this paper
• Systemic treatment options for advanced biliary tract carcinoma

  2020cites this paper
• Cholangiocarcinoma: investigations into pathway-targeted therapies

  2020cites this paper
• Novel biomarkers and the future of targeted therapies in cholangiocarcinoma: a narrative review.

  2020influential citation
• Emerging pathways for precision medicine in management of cholangiocarcinoma.

  2020cites this paper
• Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy

  2020cites this paper
• Continuum of care for advanced biliary tract cancers.

  2020cites this paper
• Experimental HER2- targeted therapies for biliary tract cancer

  2020influential citation
• Liver and Bile Duct Cancer

  2020cites this paper
• Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow

  2020cites this paper
• Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials

  2019cites this paper
• HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma

  2019cites this paper
• Gallbladder Cancer: Current and Emerging Therapies

  2019cites this paper
• Current omics-based biomarkers for cholangiocarcinoma

  2019cites this paper
• Cholangiocarcinoma: the quest for a second-line systemic treatment

  2019cites this paper
• Clinical Trials and Novel/Emerging Treatment

  2019cites this paper
• Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma.

  2019cites this paper
• Brain Metastases from Biliary Tract Cancers: A Case Series and Review of the Literature in the Genomic Era.

  2019cites this paper
• Biliary tract cancer prognostic and predictive genomics.

  2019cites this paper
• Human epidermal growth factor receptor 2-positive digestive tumors.

  2019cites this paper
• Molecular pathogenesis of gallbladder cancer: An update.

  2019cites this paper
• HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis

  2019cites this paper
• Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology

  2018influential citation
• Emerging molecular target antagonists for the treatment of biliary tract cancer

  2018cites this paper